Article
Allergan Issues Recall of Taytulla Birth Control
Author(s):
Allergan has issued a voluntary recall in the United States for a single lot of its norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules (Taytulla) physician sample packs.
Allergan has issued a voluntary recall in the United States for a single lot of its norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules (Taytulla) physician sample packs, due to the incorrect placement of placebo pills in the pack.
Caught through a physician report of the pregnancy prevention product, the lot in question has been identified by Allergan as Lot #5620706 (Expiry May 2019). The packs were of the 1 mg/20 mcg 6x28 quantity.
Specifically, the first 4 days of the capsules were packaged with 4 non-hormonal placebo capsules in place of their active counterparts. The product was distributed nationally to health care providers, according to Allergan.
Click to continue reading on MD Magazine.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
